Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Genitourinary 2

Conditions

Carcinoma, Non-Small-Cell Lung 473Neoplasms 290Breast Neoplasms 277Colorectal Neoplasms 223Neoplasm Metastasis 187Prostatic Neoplasms 168Ovarian Neoplasms 163Lung Neoplasms 154Multiple Myeloma 152Recurrence 132Melanoma 116Pancreatic Neoplasms 114Squamous Cell Carcinoma of Head and Neck 104Endometrial Neoplasms 98Stomach Neoplasms 97Leukemia, Myeloid, Acute 95Small Cell Lung Carcinoma 84Leukemia, Lymphocytic, Chronic, B-Cell 83Lymphoma, Non-Hodgkin 81Triple Negative Breast Neoplasms 80Carcinoma, Renal Cell 79Carcinoma, Hepatocellular 77Urinary Bladder Neoplasms 75Lymphoma, Large B-Cell, Diffuse 72Lymphoma, Follicular 64Advanced Solid Tumors 63Lymphoma 60Glioblastoma 57Parkinson Disease 4, Autosomal Dominant Lewy Body 55Head and Neck Neoplasms 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Metastatic Castration Resistant Prostate Cancer × 90 days × Clear all
NCT07093801 2026-05-15

Observational Study on Lutetium (177Lu) Vipivotide Tetraxetan to Treat Metastatic Castration Resistant Prostate Cancer

Novartis

Recruiting
300 enrolled
Genitourinary

Metastatic Castration Resistant Prostate Cancer

NCT05219500 2026-04-03

TATCIST

Fusion Pharmaceuticals Inc.

Phase 2 Active not recruiting
115 enrolled
Genitourinary

Metastatic Castration Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡